Brown Advisory’s Cytokinetics CYTK Stock Holding History

Brown Advisory’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$48.6M	Sell	570,664 -43,991	-7%	-$3.16M	0.08%	204
2026 Q1	$40.5M	Sell	614,655 -116,499	-16%	-$7.4M	0.07%	218
2025 Q4	$46.5M	Sell	731,154 -181,032	-20%	-$11.3M	0.06%	212
2025 Q3	$50.1M	Sell	912,186 -83,113	-8%	-$3.42M	0.07%	199
2025 Q2	$32.9M	Sell	995,299 -91,001	-8%	-$3.17M	0.04%	250
2025 Q1	$43.7M	Buy	1,086,300 +9,869	+0.9%	+$454K	0.06%	204
2024 Q4	$50.6M	Sell	1,076,431 -89,560	-8%	-$4.65M	0.06%	205
2024 Q3	$61.6M	Buy	1,165,991 +403,442	+53%	+$22.5M	0.08%	184
2024 Q2	$41.3M	Buy	762,549 +3,015	+0.4%	+$182K	0.05%	235
2024 Q1	$53.3M	Buy	+759,534	New	+$58.7M	0.07%	200
2022 Q1	–	Sell	-11,759	Closed	-$536K	–	1148
2021 Q4	$536K	Buy	+11,759	New	+$454K	﹤0.01%	855

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Brown Advisory's CYTK Position: Q2 2026 in Review

Brown Advisory reduced its Cytokinetics (CYTK) stake by 7.2% in Q2 2026, selling an estimated $3.16M and leaving 570,664 shares worth $48.6M. The position accounts for 0.08% of the portfolio, ranked #204.

Brown Advisory first reported a position in CYTK in Q4 2021 and has held it in 11 quarters since. The position peaked at $61.6M in Q3 2024. 483 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Brown Advisory held 570,664 shares of Cytokinetics worth $48.6M as of Q2 2026.
Brown Advisory sold 43,991 Cytokinetics shares in Q2 2026, an estimated $3.16M.
Cytokinetics made up 0.08% of Brown Advisory's portfolio in Q2 2026, its #204 holding.
Brown Advisory first reported a position in Cytokinetics in Q4 2021 and has held it in 11 quarters since.
Brown Advisory's Cytokinetics position peaked at $61.6M in Q3 2024.
483 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Brown Advisory's 13F filing for Q2 2026, filed 14 Aug 2026.